Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
Robert A Kyle1, Ellen D Remstein, Terry M Therneau
1Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. kyle.robert@mayo.edu
The New England Journal of Medicine
|June 22, 2007
Related Experiment Videos
View abstract on PubMed
Summary
Smoldering multiple myeloma progression risk is linked to bone marrow plasma cells and serum monoclonal protein levels at diagnosis. Identifying these factors aids in predicting outcomes for this plasma-cell disorder.
Area of Science:
- Hematology
- Oncology
Background:
- Smoldering multiple myeloma is an asymptomatic plasma-cell disorder with a high risk of progression to symptomatic disease.
- Prognostic factors influencing progression and outcomes remain unclear.
Purpose of the Study:
- To identify prognostic factors for progression in smoldering multiple myeloma.
- To develop a risk-stratification model for predicting outcomes.
Main Methods:
- Reviewed medical records of 276 patients diagnosed with smoldering multiple myeloma (1970-1995).
- Analyzed bone marrow specimens and patient follow-up data.
- Utilized International Myeloma Working Group diagnostic criteria.
Main Results:
- Symptomatic multiple myeloma or amyloidosis developed in 59% of patients over 2131 person-years.
- Progression risk was highest in the first 5 years (10% annually), decreasing over time.
- Key risk factors identified: serum monoclonal protein level, urinary light chain, bone marrow involvement, and immunoglobulin levels.
Conclusions:
- Bone marrow plasma cell proportion and serum monoclonal protein level at diagnosis are critical predictors of progression risk.
- A risk-stratification model combining these factors identifies distinct prognostic groups.